LP-284
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Lymphomas
Conditions
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Trial Timeline
Jan 3, 2023 → Nov 30, 2028
NCT ID
NCT06132503About LP-284
LP-284 is a phase 1 stage product being developed by Lantern Pharma for Relapsed or Refractory Lymphomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06132503. Target conditions include Relapsed or Refractory Lymphomas, Advanced Solid Tumor.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Lymphomas were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06132503 | Phase 1 | Recruiting |
Competing Products
20 competing products in Relapsed or Refractory Lymphomas